ATE386537T1 - Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette - Google Patents

Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette

Info

Publication number
ATE386537T1
ATE386537T1 AT95924766T AT95924766T ATE386537T1 AT E386537 T1 ATE386537 T1 AT E386537T1 AT 95924766 T AT95924766 T AT 95924766T AT 95924766 T AT95924766 T AT 95924766T AT E386537 T1 ATE386537 T1 AT E386537T1
Authority
AT
Austria
Prior art keywords
gamma chain
receptor
cytokine receptor
cell
interleukin
Prior art date
Application number
AT95924766T
Other languages
English (en)
Inventor
Vassiliki Boussiotis
Lee Nadler
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE386537T1 publication Critical patent/ATE386537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT95924766T 1994-07-01 1995-06-30 Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette ATE386537T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/270,152 US6576236B1 (en) 1994-07-01 1994-07-01 Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain

Publications (1)

Publication Number Publication Date
ATE386537T1 true ATE386537T1 (de) 2008-03-15

Family

ID=23030131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95924766T ATE386537T1 (de) 1994-07-01 1995-06-30 Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette

Country Status (10)

Country Link
US (2) US6576236B1 (de)
EP (2) EP1958966A2 (de)
JP (2) JPH10502372A (de)
AT (1) ATE386537T1 (de)
AU (1) AU2915295A (de)
CA (1) CA2194239A1 (de)
DE (1) DE69535713T2 (de)
DK (1) DK0768890T3 (de)
ES (1) ES2299174T3 (de)
WO (1) WO1996001122A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3362192B2 (ja) * 1994-12-06 2003-01-07 味の素株式会社 検査方法及び検査薬
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
CA2220226C (en) * 1995-05-04 2008-10-21 Carl H. June Improved methods for transfecting t cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
DE59605711D1 (de) * 1995-10-11 2000-09-14 Arteva Tech Sarl Schwerentflammbare Sicherheitsgurte enthaltend phosphor-modifizierte Polyesterfasern
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
ATE476496T1 (de) * 1996-03-04 2010-08-15 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
US5807743A (en) * 1996-12-03 1998-09-15 Ribozyme Pharmaceuticals, Inc. Interleukin-2 receptor gamma-chain ribozymes
JP2001511649A (ja) * 1997-02-07 2001-08-14 トーマス・ジェファーソン・ユニバーシティ サイトカインレセプターガンマ鎖のペプチド模倣物
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
AU2001234784A1 (en) * 2000-02-04 2001-08-14 Bioseek Compositions and methods for reducing autoimmunity
MXPA03008959A (es) * 2001-04-02 2004-10-15 Wyeth Corp Pd-1, un receptor para b7-4 y sus usos.
EP1663197B1 (de) 2003-09-09 2007-12-05 Fumapharm AG Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
AU2007214426A1 (en) * 2006-02-16 2007-08-23 Nascent Biologics, Inc. Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
HRP20220902T3 (hr) 2007-02-08 2022-10-14 Biogen Ma Inc. Pripravci i njihova upotreba u liječenju multiple skleroze
JP2016523102A (ja) * 2013-06-24 2016-08-08 アントフロゲネシス コーポレーション Ｔ細胞を増殖させるための方法
EA202192090A1 (ru) 2019-02-01 2021-10-20 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки против гамма-цепи рецептора il2

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1892296A1 (de) 1988-09-02 2008-02-27 Dyax Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
IL92382A (en) 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
WO1991001145A1 (en) * 1989-07-25 1991-02-07 Regents Of The University Of Minnesota Pokeweed antiviral protein - monoclonal antibody conjugates
EP1690935A3 (de) 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
AU661979B2 (en) * 1990-09-06 1995-08-17 Schering Corporation Use of IL-4 to treat solid tumors
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
MX9305070A (es) * 1992-08-21 1994-04-29 Genentech Inc Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
EP0672131B1 (de) 1992-10-30 2003-12-17 The General Hospital Corporation Ein neues zellzyklus kontrollprotein
EP0621338A3 (de) * 1993-04-21 1997-10-29 Ajinomoto Kk Die Interleukin-2 Antwort blockierende Immunsuppressor.
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain

Also Published As

Publication number Publication date
EP0768890A1 (de) 1997-04-23
ES2299174T3 (es) 2008-05-16
DK0768890T3 (da) 2008-06-09
AU2915295A (en) 1996-01-25
DE69535713T2 (de) 2009-03-19
US6576236B1 (en) 2003-06-10
CA2194239A1 (en) 1996-01-18
DE69535713D1 (de) 2008-04-03
US20040037808A1 (en) 2004-02-26
JPH10502372A (ja) 1998-03-03
WO1996001122A1 (en) 1996-01-18
JP2007112815A (ja) 2007-05-10
EP1958966A2 (de) 2008-08-20
EP0768890B1 (de) 2008-02-20

Similar Documents

Publication Publication Date Title
ATE386537T1 (de) Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette
ATE47866T1 (de) Copolymere auf basis von maleinsaeureanhydrid und alpha, beta-ungesaettigten verbindungen, ein verfahren zu ihrer herstellung und ihre verwendung als paraffininhibitoren.
DK0597960T3 (da) Behandling af cellepopulationer
DE3577564D1 (de) Polymere zur verwendung als hilfsmittel in der filtrationskontrolle fuer bohrfluessigkeiten.
ATE25085T1 (de) Neue lichtstabilisatoren fuer polymere.
DE3750800D1 (de) Verfahren zur Erzeugung von Anzeigen mit veränderlichen Skalen.
ATE266671T1 (de) Nukleinsäuresynthese unter verwendung von mittels licht abspaltbaren schutzgruppen
DE3486052T2 (de) Verfahren zur unabaenderlichen bindung von proteinen auf polystyren-oberflaechen mit aufrechterhaltung ihrer biologischen wirksamkeit, derart erhaltene polystyren-oberflaechen und ihre verwendung.
DE3671640D1 (de) Kationische emulsionen von bitumen-polymerartigen bituminoesen bindemitteln und kationisches emulgiersystem, unter anderem verwendbar zur erhaltung derselben.
DE3583189D1 (de) Carbazole und ihre verwendung als photoinitiatoren von photopolymerisierbaren, ungesaettigten verbindungen.
DE3766500D1 (de) Verfahren zur dehalogenierung von halogenierten kohlenwasserstoffen.
ATA901987A (de) Vorrichtung zur erzeugung von gas aus festen brennstoffen
DE69314024T2 (de) NEUE GABAa-REZEPTORSUBTYPEN UND VERFAHREN ZUM SCREENING VON ARZNEIMITTELVERBINDUNGEN UNTER VERWENDUNG VON GABAa-REZEPTORSUBTYPEN BINDENDE IMIDAZOCHINOXALINE UND PYRROLOPYRIMIDINE
DE3485319D1 (de) Rekombinante dns, diese rekombinante dns enthaltende bakterien, und verfahren zur herstellung von l-threonin oder l-isoleucin unter verwendung dieser bakterien.
ATA171787A (de) Heizanlage zum verbrennen von festen brennstoffen
NO854710L (no) Fremgangsmåte for kontroll og styring av injeksjonssonens utstrekning ved jetinjisering av herdbart bindemiddel i jordarter, samt anordning for gjennomføring av fremgangsmåten.
DE59001452D1 (de) Verfahren zur optimierung der verbrennung von kraftstoffen bei minimaler co-emission und vorrichtung zur durchfuehrung des verfahrens.
DE3480928D1 (de) 5-substituierte 2-pyrimidinon-nukleoside und verfahren zu ihrer verwendung.
ATE45746T1 (de) Substituierte o-acyl-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung.
DE3851493D1 (de) Methode und anlage zur erzeugung von lichtstrahlung aus freiem positronium.
ATE153997T1 (de) Entfärbung von alkylierten diarylaminen
BR9604947A (pt) Genes que codificam polipept¡deos (lsirf) fatores reguladores de interferon linfoc¡tico
AT375954B (de) Verfahren zur herstellung von selbstvernetzenden, kathodisch abscheidbaren etl-bindemitteln auf basis modifizierter phenol-novolake
DE3768433D1 (de) Durch protonierung mit saeure wasserverduennbare bindemittel.
DE68901943T2 (de) Verfahren zur dotierung von zink-selenid-einkristall.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties